Objective. To determine nephritis outcomes in a prospective multi-ethnic/racial SLE inception cohort.
Introduction
Renal disease affects 38% of patients with SLE, with a range of 1269% [1] . The frequency and severity is increased in patients with African, Hispanic and Asian ancestry [1] . Although a common early manifestation, it can occur at any time in the disease course [2] . The presentation varies from subclinical laboratory abnormalities to overt nephritis and nephrotic syndrome. Despite recent advances, some studies report progression to end-stage renal disease (ESRD) and mortality has not declined in the last decade [3, 4] .
Improved outcomes of nephritis result from better treatment of both primary pathogenetic mechanisms and secondary co-morbidities. Administration of i.v. CYC [5, 6] and oral MMF are effective for induction [79] or maintenance therapy [10, 11] . Open-label studies of targeted Bcell depletion therapies have been positive [12, 13] , although unconfirmed in controlled studies [14] . These immunomodulatory strategies and treatment of comorbidities have been incorporated into recent treatment guidelines [15, 16] . The value of future treatment strategies will be determined by comparison with current standard of care.
Between 1999 and 2012 the Systemic Lupus International Collaborating Clinics (SLICC) established the SLICC inception cohort for the long-term study of clinical outcomes in SLE. The objective of the current study was to evaluate the short-term outcomes, as reflected by health-related quality of life (HRQoL), ESRD and death in patients with LN receiving standard of care in this international multi-ethnic/racial observational cohort of newly diagnosed SLE patients.
Patients and methods

Research study network
The study was conducted by members of the SLICC network [17] . Data were collected per protocol at enrolment and annually (±6 months) thereafter and entered into a centralized database. Each of the participating centre's institutional research ethics review boards approved the SLICC inception cohort study, including this present analysis.
Patients
Patients fulfilled the ACR classification criteria for SLE [18] and provided written informed consent for the SLICC inception cohort. Enrolment occurred up to 15 months following diagnosis. Demographic variables included age, gender, race/ethnicity and education. Medication history and lupus-related variables, such as the SLEDAI-2K [19] and SLICC/ACR damage index (SDI), were also recorded [20] . Laboratory testing included haematology, chemistry and immunology required for SLEDAI-2K and SDI scores. Patient self-reported HRQoL was measured by the subscale and summary scores of the Short Form (36 questions) health survey questionnaire (SF-36) [21] .
LN
Nephritis was identified by the renal disorder variable of the ACR classification criteria [18, 22] and/or biopsy evidence of nephritis as per the International Society of Nephrology and Renal Pathology Society (ISN/RPS) criteria [23] .
Renal variables and data collection
The SLICC inception cohort was not initially established for the study of renal disease. Thus, some renal data was garnered retrospectively by chart review. The ISN/RPS classification [23] and activity/chronicity scores of Austin et al. [24] were derived from renal biopsy reports. The National Kidney Foundation (NKF) classification of chronic kidney disease (CKD) [25] and estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease equation [26] were determined at each assessment. Estimated proteinuria (ePrU) was measured by either 24-h urine collection or spot urine total protein:creatinine ratio [27, 28] . ESRD was determined from the SDI renal variable [29] .
At each assessment, patients were assigned to one of three eGFR and ePrU states. For eGFR: state 1 (eGFR: >60 ml/min); state 2 (eGFR: 3060 ml/min); and state 3 (eGFR: <30 ml/min). For ePrU: state 1 (ePrU: <0.25 g/day); state 2 (ePrU: 0.253.0 g/day); and state 3 (ePrU: >3.0 g/ day).
Statistical analyses
Descriptive statistics were used to summarize enrolment data, and Chi-square tests and t-tests were performed as appropriate. A simple ordinal regression based on generalized estimating equation (GEE) methods was used to assess the trends of eGFR and ePrU states as well as NKF classification of CKD over time after LN diagnosis. Non-parametric estimates of the cumulative incidence function for the time until ESRD and death were calculated using KaplanMeier-like methodology [30] . A Cox regression with a time-varying covariate was also used to examine the effect of LN diagnosis on the competing risks of ESRD and death. Analyses of HRQoL outcomes at enrolment or at diagnosis of LN were based on simple linear regression models. For analyses of the HRQoL longitudinal outcomes, linear regression models with GEE were used to take into account the correlation between multiple observations within patients. Hypothesis tests for the significance of regression parameters were performed using Wald tests (Cox regression) and score tests (GEE analyses), and 95% CIs were calculated. (Table 1) .
Results
Patients
At enrolment, the mean (S.D.) disease duration was 0.5 (0.3) years and patients had low SLEDAI-2K and SDI scores while receiving a range of lupus medications. Annual assessments varied from 1 to 13, with a mean follow-up of 4.6 (3.4) years. Eighty patients (4.4%) were lost to follow-up for reasons that included relocation, living excessive distance from the clinic, referral to a nonparticipating site, voluntary withdrawal and change in insurance status.
Onset and characteristics of patients with LN LN occurred in 700 (38.3%) patients: 566/700 (80.9%) at the enrolment visit and 134/700 (19.1%) during follow-up (Fig. 1) . Renal biopsies were performed on 395/700 (56.4%) patients, the majority (86.6%) when nephritis was first suspected; in 377/395 (95.4%) these were of sufficient quality to identify ISN/RPS classes (%): I: 9 (2. Patients with LN at enrolment were younger and more frequently men and of African, Asian and Hispanic race/ ethnicity (Table 1) . Nephritis patients had a higher frequency of ACR classification criteria [18] for serositis, neurological disorder and immunological disorder and a lower frequency of mucocutaneous disease, arthritis and ANA. The higher mean total SLEDAI-2K in patients with nephritis was due to the inclusion of renal variables in the index score. Both the mean total and similarly adjusted SDI score was higher in patients with LN. Corticosteroids and immunosuppressive drugs were used more frequently and antimalarials less frequently (49.1%) in the nephritis group at enrolment, although antimalarial use increased to 72% over the study. Hypertension was more frequent in patients with nephritis.
Of the 1827 patients at the enrolment visit, 96 (5.3%) were ANA negative. There were no statistically significant differences in ACR classification criteria between ANApositive and ANA-negative nephritis patients, with the exception of a higher frequency of immunological disorder in the ANA-positive group (88.4% vs 47.5%, P < 0.001). Twenty-seven (8/40 ANA-negative nephritis group and 19/56 in non-nephritis group) of the 96 patients who were ANA negative at enrolment became ANA positive during the study.
Outcome of LN
Adjusting for gender, age at enrolment and race/ethnicity, a Cox regression analysis on the competing risks of ESRD and death, with the diagnosis of LN used to define a timedependent covariate, indicated that once patients were diagnosed with LN, they had higher risks of developing ESRD [hazard ratio (HR) = 44.7, 95% CI: 6.1, 329.7; P < 0.001] and death (HR = 3.2, 95% CI: 1.6, 6.5; P = 0.002).
The estimated cumulative incidence of ESRD (as defined by the SDI) for the entire cohort at 10 years following enrolment was 4.3% (95% CI: 2.8%, 5.8%) (Fig. 2a) . For all patients with LN, the cumulative incidence of ESRD at 10 years after the diagnosis of LN was 10.1% (95% CI: 6.6%, 13.6%) (Fig. 2b) . Excluding patients who ever developed LN, the estimated cumulative incidence of ESRD was 0.5% (95% CI: 0%, 1.4%) (Fig. 2c ), albeit that this is an ad hoc analysis because some patients are excluded on the basis of developing LN following the enrolment visit.
The estimated cumulative incidence of death from all causes for the entire cohort at 10 years after enrolment was 4.4% (95% CI: 2.7%, 6.1%) (Fig. 2a) . Patients with LN at enrolment and those who never developed LN had a cumulative incidence of death at 10 years of 5.0% (95% CI: 2.3%, 7.6%) (Fig. 2d ) and 3.6% (95% CI: 0.9%, 6.2%) (Fig. 2d) , respectively. In light of the very significant association between time-dependent LN status and death in the Cox regression, these overlapping confidence intervals are likely due to the limited data available to estimate cumulative incidences at single time points late in the follow-up period. An overall test of a difference in these curves using the log-rank test of no difference is significant (P = 0.03). The number of patients at the time points for curves in Fig. 2 are provided in a supplementary Table  S1 , available at Rheumatology Online. For patients with LN, the cumulative incidence of death at 10 years following the diagnosis of LN was 5.9% (95%CI: 3.3%, 8.4%) (Fig. 2b) . Of the 39 patients who died, only 1 was due to ESRD. The others were attributed primarily to cardiorespiratory causes (18) , infection (8) , neurological disease (6), malignancy (2) and miscellaneous causes (4). Additional analyses were performed in which the use of antimalarials at enrolment was added to the Cox regression analyses [details are provided in a supplementary Table S2, available The number and proportion of patients in each of the three eGFR and ePrU states and CKD stage at LN diagnosis and at the third and fifth annual follow-up assessment after LN diagnosis is summarized in Table 2 . There was no demonstrable change in the distribution of eGFR states, but there was a markedly lower frequency of ePrU state 3 over time (P < 0.001). There was no significant overall change in the proportion of patients with the six stages of CKD.
LN and HRQoL at enrolment and follow-up SF-36 subscale and summary scores were not significantly lower in patients with LN at enrolment compared with the enrolment values for patients who never developed nephritis. However, the subscale scores for Bodily pain and Vitality scores were lower in non-LN patients (data not shown). Patients with LN and eGFR state 3 at diagnosis had significantly lower scores in three subscales (Physical function, Role physical and Bodily pain) (Fig. 3) and in the Physical component summary score of the SF-36 (P < 0.01). These findings were similar when adjustment was made for age at SLE diagnosis, gender, location, race/ethnicity, SLEDAI (without renal variables) and medication. No adjustment could be made for SDI 
or dialysis).
The discrepancy between the number of patients in eGFR states and CKD classification stages is due to methodological differences for making these determinations: eGFR is measured at a specific time point, whereas CKD classification reflects a persistent abnormality in eGFR for 53 months and sometimes requires a determination of proteinuria or renal imaging. eGFR: estimated glomerular filtration rate; ePrU: estimated proteinuria; NKF: National Kidney Foundation; CKD: chronic kidney disease. scores due to the short disease duration at enrollment, which precluded determining an SDI score in many patients. For ePrU states at the same assessments, the Role physical scores were lower in ePrU state 3 [28.6 (40. Adjusting for years after LN diagnosis, there were statistically significant but relatively small declines in SF-36 physical component summary and mental component summary values for patients in eGFR or ePrU states 2 and 3 over time (Table 3) . After adjustment for gender, age at SLE diagnosis, race/ethnicity, SLEDAI (without renal variables), medication and SLICC damage score (without renal variables), all but the relationship between physical component summary and ePrU states remained significant (Table 3 ). There was no statistical evidence for the dependence of these relationships on time.
Discussion
Since Merrell and Shulman [31] reported a 50% 4-year survival in the 1950s, renal and overall survival in patients with LN have steadily improved [32, 33] . This is attributed to multiple factors, including earlier diagnosis and access to health care, advances in therapy with immunosuppression, dialysis and transplantation and treatment of comorbidities. However, other studies have suggested that ESRD and associated mortality have not changed over the past two decades [3, 4] . The current prospective, observational study reflects the outcome of LN in a large international multi-racial/ethnic disease inception cohort of SLE patients receiving standard of care for up to 12 years. Although the outcomes are generally favourable, the findings indicate room for further improvement.
The SLICC inception cohort, the largest of its kind, is well placed to address the objectives of the current study. The frequency of the initial manifestations of SLE, as reflected by individual ACR classification criteria [18] , is comparable with that of another large cohort [34] and indicates a general lupus population without major selection bias. At presentation, patients had moderate global SLE disease activity and mild organ damage. The cumulative frequency of nephritis of 38.3% in our cohort is very similar to the overall incidence of 37.8% in 2290 SLE patients enrolled in studies from North America, Europe and the Middle East [1] . The predilection for nephritis to present around the time of diagnosis of SLE has also been noted in another previous large observation study [35] . Other features such as a higher frequency of nephritis at a younger age [36, 37] , in men [35, 38] and in patients of non-Caucasian race/ethnicity [3537, 39] , and a higher frequency of co-morbidities such as hypertension [40, 41] provide further evidence for the validity of the cohort and generalizability of the findings. More frequent use of corticosteroids and immunosuppressive agents with nephritis is to be expected and is in line with current treatment guidelines [15, 16] .
The outcome of LN has frequently been determined by total and renal survival, changes in renal function and achievement of partial or complete remission, albeit variably defined. In the current study, we also selected the hard end-points of total and renal survival, the more frequent and more sensitive outcome of clinically meaningful defined states for renal function and ePrU, and the association with the less tangible but quantifiable outcome of HRQoL.
In a European multicentre study of 1000 prevalent SLE patients [34] , 97.1% of whom were white and followed between 1990 and 2000, the overall 10-year survival was 92%. In the 279 (27.9%) patients who presented with nephritis at onset of the study, the 10-year survival was 88%, compared with 94% in patients without nephropathy. In the current study the estimated 10-year survival in the entire cohort and in patients with and without nephritis was 95.7, 94.5 and 96%, respectively. Although this may represent improvement in the outcome of LN, a more likely explanation is the inherent difference between a prevalent and an inception cohort. For example, the mean disease duration at enrolment into the European [42] and SLICC cohorts was 6 years and 6 months, respectively, and longer disease duration is an independent risk for mortality. In both studies, death was attributed to multiple causes and followed ESRD in only 1/40 (2.5%) patients in our study.
The frequency of ESRD, as defined by haemodialysis or renal transplantation, in the European multicentre study [34] between 1990 and 2000 was 37/1000 (3.7%). Two recent registry and population health studies in the USA [36, 37] , involving 1156 and 2278 prevalent SLE patients over 3 years (200204), reported an overall frequency of ESRD of 6.713.3%, depending upon the case definition www.rheumatology.oxfordjournals.org for ESRD. In both studies, there was a strikingly higher frequency of LN and ESRD in African Americans, who were also the major racial/ethnic group. In the current study, the cumulative incidence of ESRD (as defined by stage 5 of the NKF classification of CKD) at 5 years was 3.3% and at 10 years following enrolment was 4.3% (as defined in the SDI). Despite methodological differences in study design, it is clear that ESRD and increased mortality persist with current treatment modalities for LN. The changes in the transition of ePrU states over 3 and 5 years indicate responsiveness to therapy for ePrU over this time frame. Renal function, reflected by different eGFR states and the CKD classification, did not change appreciably. Small changes over time in the eGFR state distribution cannot be excluded, due to the limited duration of follow-up, but these findings do suggest that some patients with LN do not respond, in terms of a marked improvement in renal function, to current treatment modalities, either due to inefficacy, non-adherence or toxicity necessitating discontinuation of medication.
Relatively few studies have examined HRQoL as a primary outcome in patients with LN. Three studies [4345] have found that those undergoing treatment for severe LN have clinically relevant changes in HRQoL up to 1 year after the commencement of treatment, as quantified by SF-36 scores. In the current study, HRQoL summary scores were not lower for patients with nephritis at enrolment when compared with patients who never developed nephritis. However, patients with the most severe nephritis, as indicated by higher eGFR and ePrU states, had lower SF-36 subscale and summary scores. This association with lower HRQoL was found in both cross-sectional and longitudinal analyses, even after adjusting for multiple potential confounders. Thus, stratification of patients by severity of LN reveals significant associations with HRQoL.
There are a number of limitations to the current study. First treatment decisions were made on the basis of the physician's recommendation and patient preference rather than study protocol. However, this reflects what occurs in clinical practice and is a strength of the study. Second, the SLICC network is based within academic medical centres with a special interest in lupus, and our data may not fully reflect community clinical practice. Third, the frequency of renal biopsy was lower than expected. Recent guidelines [15, 16] encourage performing renal biopsy in all SLE patients with possible renal disease. This permits confirmation of the diagnosis, characterization of glomerular disease and a determination of overall disease activity and renal scaring, all of which inform treatment. Despite these advantages, previous observational cohort studies have indicated a highly variable biopsy rate in 36.8% of 266 [46] , 55% of 438 [47] , 77% of 26 [48] and 96% of 127 [49] patients with a clinical diagnosis of LN. The reasons for not doing a renal biopsy on patients in our cohort were multiple and included medical contraindication, lack of access due to under-insurance in a fee-for-service system, patient refusal and a low likelihood of influencing the treatment plan, due to other major organ involvement. Finally, our study was based upon a disease inception cohort, and thus the disease duration was shorter and age at enrolment younger than what is seen in prevalent cohorts of lupus cases. As both factors are associated with chronic kidney disease, further followup is necessary to determine the long-term outcome of LN in this cohort.
Despite these limitations, the study provides useful information on the frequency, characteristics and expectations for outcome in patients with LN receiving current standard of care. Most of the findings are applicable to SLE patients in general and set the benchmark for planning future clinical trials of novel therapeutic agents and protocols.
